Summary
CC-1065 is a unique alkylating agent that preferentially binds in the minor groove of double-stranded DNA at adenine-thymine-rich sites. Although it has broad antitumor activity in preclinical models its development was discontinued because of deaths observed during preclinical toxicology studies. Adozelesin is a potent synthetic analog that was chosen for clinical development because it had a similar preclinical antitumor spectrum, but did not produce deaths similar to CC-1065 at therapeutic doses. Phase I evaluations using a variety of Adozelesin treatment schedules have been conducted. This report describes our experience using a multiple dose treatment schedule. Endpoints including antitumor response, maximum tolerated dose, dose limiting toxicity as well as other toxicities and the recommended Phase II starting dose were determined. Adozelesin was given as a 10 minute IV infusion for 5 consecutive days every 21 days or upon recovery from toxicity. The dose range evaluated was 6–30 mcg/m2/day. All patients had refractory solid tumors and had received prior cytotoxic treatment. Thirty-three patients (22 men: 11 women) were entered onto the study and 87 courses were initiated. Dose limiting toxicity was cumulative myelosuppression (leucopenia, thrombocytopenia). The maximum tolerated dose was 30 mcg/m2/day. The only other significant toxicity was an anaphylactoid syndrome that occurred in 2 patients. A partial response was observed in a patient with refractory soft tissue sarcoma. The recommended Phase II starting dose of Adozelesin using a 10 minute IV infusion for 5 consecutive days is 25 mcg/m2/day to be repeated every 4–6 weeks to allow recovery from myelotoxicity, based on our experience. Additional Phase I and II studies with Adozelesin are recommended.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Colvin M, Chabner BA: Alkylating Agents. In: Chabner BA, Collins JM (eds) Cancer Chemotherapy: Principles and Practice. J.B. Lippincott Co., New York, 1990, pp 276–313
Hanka LJ, Dietz A, Gerpheide SA, Kuentzel SL, Martin DG: CC-1065 (NSC 298223), a new antitumor antibiotic. Production,in vitro biological activity, microbiological assays and taxonomy of the producing microorganism. J Antibiot 31(12):1211–1217, 1978
Martin DG, Chidester CG, Duchamp DJ, Mizak SA: Structure of CC-1065 (NSC 298223), a new antitumor antibiotic. J Antibiot 33:902–903, 1980
Li LH, Swenson DH, Schpok SL, Kuentzel SL, Dayton BD, Krueger WC: CC-1065 (NSC 298223), a novel antitumor agent that interacts strongly with double-stranded DNA. Cancer Res 42:999–1004, 1982
Swenson DH, Li LH, Hurley LH, Rokem GL, Petzold GL, Dayton TL, Lin AH, Krueger WC: Mechanism of interaction of CC-1065 (NSC 298223) with DNA. Cancer Res 42:843–844, 1982
Hurley LH, Reynolds VL, Swenson DH, Petzold GL, Scahill TA: Reactions of the antitumor antibiotic CC-1065 with DNA: structure of a DNA adduct with DNA sequence specificity. Science 226:843–844, 1984
Bhuyan BK, Crampton SL, Adams EG: Cell cycle effects of CC-1065. Cancer Res 43:4227–4232, 1983
McGovern JP, Clarke GL, Pratt EA, DeKoning TF: Preliminary toxicity studies with the DNA-binding antibiotic CC-1065. J Antibiot 37:63–70, 1984
Warpehoski MA, Gebhard I, Kelly RC, Krueger WC, Li LH, McGovern JP, Prairie MD, Wichienski N, Wiergenga W: Stereoelectronic factors influencing the biological activity and DNA interactions of synthetic antitumor agents modeled on CC-1065. J Med Chem 31: 590–603, 1988
Li LH, Kelly RC, Warpehoski MA, McGovern JP, Gebhard I, DeKoning TF: Adozelesin, a selected lead among cyclopropapyrroloindole analogs of the DNA-binding antibiotic, CC-1065. Invest New Drugs 9:137–148, 1991
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Amer J Clin Oncol 5:649–655, 1982
Wieland KL, Dooley TP:In vitro andin vivo bonding by the CC-1065 analogue U-73975. Biochemistry 30:7559–7565, 1991
Boger DL: The duocarmycins: synthetic and mechanistic studies. Acc Chem Res 28:20–29, 1995
Fleming GF, Ratain MJ, O'Brien SM, Schilsky RL, Hoffman PC, Richards JM, Vogelzang NJ, Kasunic DA, Earhart RH: Phase I study of adozelesin administered by 24 hour continuous intravenous infusion. J Natl Cancer Inst 86:368–372, 1994
Shamdas GJ, Alberts DS, Modiano M, Wiggins C, Power J, Kasunic DA, Elfring GL, Earhart RH: Phase I study of adozelesin (U-73,975) in patients with solid tumors. Anti-cancer Drugs 5:10–14, 1994
Lassus M, Scott D, Leyland-Jones B: Allergic reactions (AR) associated with cremophor (C) containing antineoplastics (ANP): Proc ASCO 4:268, 1985
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Foster, B.J., LoRusso, P.M., Poplin, E. et al. Phase I trial of Adozelesin using the treatment schedule of daily × 5 every 3 weeks. Invest New Drugs 13, 321–326 (1995). https://doi.org/10.1007/BF00873138
Issue Date:
DOI: https://doi.org/10.1007/BF00873138